"Those 14 medication positions that were recalled from the market under yesterday's decree are no longer available either in pharmacies or healthcare institutions," Gytis Andrulionis said at a news conference on Tuesday.
Ranitidine-containing medicines are very popular in Lithuania, with 88,000 packs of these drugs sold in the country monthly on average, he said, adding that the drugs can be replaced with similar medications.
The recall applies to all medicines whose active ingredient is ranitidine hydrochloride, including Ranitidinas Sanitas, Ranitidine Accord, Ranigast, Ranitidine, Ranitidine Actiopharma and Raniberl.
The market regulator said the decision was due to the discovery of N-Nitrosodimethylamine (NDMA) in ranitidine made by India's Saraca Laboratories Limited and Spain's Union Quimico Farmaceutica.
The ban will remain in effect until marketing authorization holders provide documents proving that their medicines do not contain NDMA, it said.
Ranitidine is an an antacid used for treating short-term gastrointestinal disorders and ulcers.
The World Health Organization and the EU's International Agency for Research on Cancer classify NDMA and similar substances as potentially carcinogenic for humans.
The Lithuanian government will on Wednesday consider merging three state research institutes into one.
Monaco-registered GRH International has decided to establish its new R&D and manufacturing unit...
Lithuanian President Gitanas Nauseda , currently in Brussels, said on Friday he would seek to ensure...
11.22 million euros has been offered for the historic central post office building in central...